Evidence-Based Summary
Selank and Epitalon are two specialized regulatory peptides originating from Russian peptide research programs that address distinct dimensions of nervous and neuroendocrine health. Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide derived from the endogenous immunomodulatory peptide tuftsin, modified with a Pro-Gly-Pro sequence to resist enzymatic degradation. Administered intranasally, Selank operates primarily as a non-sedating anxiolytic and immunomodulator: it enhances allosteric GABA-A receptor signaling, inhibits enkephalin-degrading enzymes to sustain endogenous opioid peptide levels, and modulates interferon expression, significantly reducing generalized anxiety and emotional stress without benzodiazepine-like sedation or dependence. In contrast, Epitalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide modeled after bovine pineal extract (Epithalamin), developed by Professor Vladimir Khavinson. Rather than acting as an acute anxiolytic, Epitalon functions as a systemic epigenetic bioregulator that targets the neuroendocrine aging axis: it crosses cellular membranes to bind DNA promoter regions, stimulating chromatin decondensation, restoring nocturnal pineal melatonin secretion in aging organisms, and inducing telomerase catalytic activity (hTERT) in human somatic cells in vitro. While Selank is an officially registered medicine in Russia for generalized anxiety and neurasthenia, Epitalon remains an unapproved experimental bioregulator studied in gerontology and longevity models. Neither substance is approved by the U.S. FDA or European EMA.
Quick Comparison: Selank vs Epitalon
A high-level comparison of molecule class, molecular receptor targets, FDA regulatory approvals, and verified clinical programs.
| Feature | Selank | Epitalon |
|---|---|---|
| Biological lineage | Derived from immunomodulatory tetrapeptide Tuftsin | Derived from bovine pineal gland peptide extract (Epithalamin) |
| Primary indication / scope | Generalized anxiety, emotional tension, stress resilience | Circadian entrainment, pineal health, cellular senescence |
| Peptide structure | 7 amino acids: Thr-Lys-Pro-Arg-Pro-Gly-Pro (751.9 Da) | 4 amino acids: Ala-Glu-Asp-Gly / AEDG (390.3 Da) |
| Neurochemical target | GABA-A allosteric modulation, enkephalinase inhibition | Chromatin remodeling, pineal melatonin, hTERT induction |
| Immediate psychological effect | Reduces acute anxiety and autonomic stress reactivity | No acute psychoactive effect; subtle circadian sleep support |
| Sedative / Addiction liability | Non-sedating; zero addictive or withdrawal potential | None; non-psychoactive bioregulator |
| Regulatory standing | Approved medicine in Russia (0.15% nasal drops) | Unapproved experimental bioregulator |
GABAergic Emotional Regulation vs Pineal Chromatin Remodeling
Contrasting synaptic neurotransmitter modulation with epigenetic chromatin regulation.
Selank: GABA-A Modulation & Enkephalin Preservation
Primary Target: GABA-A allosteric site; carboxypeptidase inhibition
Affinity Profile: High central bioactivity via olfactory transmucosal pathway
Selank binds allosterically to GABA-A receptors in the limbic system, potentiating inhibitory chloride currents that quell hyperactive autonomic arousal and anxiety. It also inhibits serum and brain peptidases that degrade leu- and met-enkephalins, maintaining endogenous opioid tone and supporting immune cytokine homeostasis.
Epitalon: Epigenetic Pineal Activation & Telomerase Induction
Primary Targets: Direct nuclear chromatin promoter binding
Affinity Profile: High sequence-specific interaction with DNA minor grooves
Epitalon penetrates cell nuclei, where its charged tetrapeptide structure interacts with core histones to decondense heterochromatin into transcriptionally active euchromatin. In the pineal gland, this upregulates serotonin N-acetyltransferase, restoring youthful circadian melatonin secretion. In somatic cells, it activates the hTERT promoter, inducing telomerase activity.
Official State Register vs Research Bioregulator
The differing commercial and legal statuses of Selank and Epitalon.
Selank Status & Formulations
Not approved by the FDA or EMA for human clinical use.
Epitalon Status & Formulations
Not approved by the FDA or EMA for human clinical use.
Critical Regulatory Distinction
Selank is an approved prescription drug on the Russian State Register of Medicines. Epitalon is not an approved pharmaceutical drug in any Western jurisdiction.
Anxiety Clinical Trials vs Long-Term Gerontology Cohorts
Contrasting psychiatric trial outcomes with aging and mortality studies.
Selank: Selank Clinical Evidence
In controlled Russian clinical trials in 62 patients with generalized anxiety disorder and neurasthenia, Selank 0.15% demonstrated anxiolytic efficacy comparable to medazepam within 3 to 5 days of initiation, with significantly lower rates of somnolence, fatigue, and memory complaints.
Epitalon: Epitalon / Epithalamin Clinical Evidence
Long-term clinical trials conducted by Khavinson et al. in elderly human cohorts demonstrated that intermittent administration of pineal peptides improved immune function, restored nocturnal melatonin production, and was associated with a statistically significant reduction in cardiovascular and overall mortality over a 12-year follow-up.
Tolerability & Adverse Effects
Both peptides exhibit high safety margins and low reported incidence of adverse events.
| Safety Consideration | Selank | Epitalon |
|---|---|---|
| Cognitive blunting / drowsiness | None (Maintains executive focus) | None (Non-sedative) |
| Withdrawal syndrome | None (No receptor downregulation) | None |
What Selank and Epitalon Have in Common
Where the two compounds overlap in biology, evidence or regulatory context.
Russian Peptide Heritage
Both peptides were developed by Soviet/Russian academic research institutes.
Non-Sedating Profiles
Neither peptide induces the daytime drowsiness or motor impairment associated with conventional sedatives.
Key Scientific & Clinical Differences
Meaningful distinctions in mechanism, strength of evidence, safety and regulatory status.
Clinical Purpose
Selank is an acute and subacute anxiolytic; Epitalon is a long-term geroprotective and pineal bioregulator.
Target System
Selank acts on synaptic GABAergic and enkephalinergic circuits; Epitalon acts on nuclear chromatin and pineal melatonin synthesis.
Length & Structure
Selank is a 7-amino-acid stabilized peptide; Epitalon is an ultra-short 4-amino-acid sequence.
Scientific Comparison vs Clinical Recommendations
Inside Peptides compares scientific evidence, receptor pharmacology, and official regulatory documents to advance public and professional understanding. We do not determine which compound is appropriate for an individual patient, rank medications with arbitrary scores, or recommend initiating or switching treatments.
Decisions about any medicine require a licensed healthcare professional who can weigh personal medical history, contraindications, interactions and monitoring needs. Unapproved peptides have no established safe use, and products sold as “research chemicals” are not the preparations studied in clinical research.
Approved Uses vs Online Claims
A critical scientific distinction between verified, FDA-approved clinical uses and unverified claims circulating on social media and vendor platforms.
Selank and Epitalon can be taken together to eliminate all stress and live forever
insufficientUnverified vendor marketing combining distinct research compounds.
While the two peptides address different physiological mechanisms (acute stress vs long-term cellular maintenance), there are zero human clinical safety trials evaluating their concurrent administration in unregulated compounded vials.
Evidence Strength Across Clinical Domains
Inside Peptides evaluates scientific certainty at the claim level. Because clinical evidence varies significantly depending on the therapeutic endpoint evaluated, each domain is assessed independently.
Anxiolysis & Stress Reduction
Selank validated in Russian psychiatric clinical trials.
Pineal Function & Melatonin Restoration
Epitalon validated in animal and long-term human gerontological cohorts.
What Research Still Doesn’t Tell Us
Identifying open scientific questions, pending active-comparator trials, and areas where long-term clinical data remain incomplete.
GABA-A Subunit Crystallography for Selank
Determining the exact allosteric binding pocket of Selank on the pentameric GABA-A receptor complex using cryo-EM.
Related Compound Profiles
Individual profiles provide full molecular datasheets, CAS numbers, preclinical histories, and compound monographs.
Related Educational Resources
Scientific & Regulatory References
Every pharmacological mechanism, clinical trial result, and regulatory approval cited on this page is traceable to official FDA prescribing documentation, ClinicalTrials.gov registries, or peer-reviewed medical publications.
-
Peer-Reviewed Article
Peptides of pineal gland and thymus prolong human life
-
In Vitro Study
GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells